Agilent Technologies Inc. - news published 468 - readings 11.757

BACK
Agilent Technologies Inc.

Agilent Technologies Inc.

Agilent Showcases Solutions and Partnerships Transforming Cancer Research and Therapeutics at AACR 2025

Agilent Technologies Inc. (NYSE: A) announced today its participation at the American Association for Cancer Research (AACR) Annual Meeting on April 25-30, 2025 in Chicago, Illinois. Innovative Agilent products and partnerships playing a crucial role in transforming cancer research, diagnostics, and therapeutics will be featured, including: ‒ Agilent Avida DNA Cancer Panels ...

Continue reading
24.04.2025
Agilent Technologies Inc.

Agilent Technologies Inc.

Agilent Receives European IVDR Certification for Companion Diagnostic Assay in Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma

Agilent Technologies Inc. (NYSE: A) today announced its PD-L1 IHC 22C3 pharmDx (Code SK006) assay has received European IVDR certification for the use as a Companion Diagnostic (CDx) to aid in the identification of gastric or gastroesophageal Junction (GEJ) adenocarcinoma patients who may be eligible for treatment with KEYTRUDA® (pembrolizumab) 1 . PD-L1 IHC 22C3 pharmDx (Cod ...

Continue reading
17.04.2025
Agilent Technologies Inc.

Agilent Technologies Inc.

Agilent to Announce Second-Quarter Fiscal Year 2025 Financial Results on May 28

SANTA CLARA, Calif.--(BUSINESS WIRE)-- Agilent Technologies Inc. (NYSE: A) will release financial results for the second quarter of fiscal year 2025 after the stock market closes on Wednesday, May 28. In addition, the company will host a conference call to discuss the results at 1:30 p.m. PDT on the same day. To join the listen-only conference call webcast, click the link on t ...

Continue reading
16.04.2025
Agilent Technologies Inc.

Agilent Technologies Inc.

2024 Annual Report Form 8-K to reflect recast business segment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 3, 2025 AGILENT TECHNOLOGIES, INC. (Exact name of registrant as specified in its charter) Delaware 001-15405 77-0518772 (State or other jurisdiction (Commis ...

Continue reading
25.03.2025
Agilent Technologies Inc.

Agilent Technologies Inc.

Agilent xCELLigence RTCA Instrumentation Applied in Recent FDA Approval

Agilent Technologies Inc. (NYSE: A) is pleased to announce its role in supporting Autolus Therapeutics' FDA approval for AUCATZYL® , a recently approved CAR T therapy. Agilent's advanced cell analysis instrumentation, specifically the xCELLigence Real-Time Cell Analysis (RTCA) technology, was applied in developing and validating AUCATZYL. The xCELLigence RTCA technology suppo ...

Continue reading
24.03.2025
Agilent Technologies Inc.

Agilent Technologies Inc.

Amendment to Statement of Changes in Beneficial Ownership (Form 4/A)

FORM 4 Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b). Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10. UNITED STATES SECURITIES AND EXCHANGE COMMISSIO ...

Continue reading
18.03.2025